Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer

Cohen, Steven J.; Alpaugh, R. Katherine; Groß, Steven; O'Hara, Shawn M.; Smirnov, Denis A.; Terstappen, Leon W.M.M.; Allard, W. Jeffrey; Bilbee, Maryann; Cheng, Jonathan D.; Hoffman, John P.; Lewis, Nancy; Pellegrino, Ann; Rogatko, André; Sigurdson, Elin R.; Wang, Hao; Watson, James C.; Weiner, Louis M.; Meropol, Neal J.

doi:10.3816/ccc.2006.n.029

Cited by 166 publications

(131 citation statements)

References 21 publications

Supporting

Mentioning

129

Contrasting

Order By: Relevance

“…In general, the detection of CTCs in colorectal cancer (CRC), independently of the method and markers [31,32]. On the other side, the correlation of CTCs with some known clinicopathological prognostic factors (e.g., T4 tumor size, perineural invasion, bowel obstruction, high preoperative CEA levels) is still uncertain [32].…”

Section: Colorectal Cancer (Crc)mentioning

confidence: 99%

Clinical studies monitoring circulating and disseminated tumor cells in gastrointestinal cancers

Eliasova

Kološtová

Kobierzycki

et al. 2014

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:Circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) are responsible for the development of metastatic disease, and may also hold the key to determining tailored therapies of advanced cancer disease. Our review summarizes the prognostic significance of the detection of CTCs and DTCs in various gastrointestinal cancers with an overview of their possible use as prognostic biomarkers. This could be used in the future as a starting point for new clinical trials focusing on the predictive potential of circulating and disseminated tumor cells. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 4, 265-277) Key words: circulating tumor cells; gastrointestinal cancer; esophageal cancer; colorectal cancer; gastric cancer; plastin3; prognosis Abbreviations AFP -alpha fetoprotein; BM -bone marrow; CD -cluster of differentiation; CEA -carcinoembryonic antigen; CHT -chemotherapy; CI -confidence interval; CTC -circulating tumor cell; CRCcolorectal carcinoma; CVB -central venous blood; CK -cytokeratin; DAPI -4,6-diamidino-2-phenylindole; DFS -disease free survival; DTC -disseminated tumor cell; EpCAM -epithelial cell adhesion molecule; FISH -fluorescent in situ hybridization; 5-FU -5-fluorouracil; HCC -hepatocellular carcinoma; HR -hazard ratio; ISET -isolation by size of epithelial tumor; ITC -isolated tumor cells; MACS -magnetic activated cell sorting; MFS -metastasis free survival; MSP -methylation specific polymerase chain reaction; MVB -mesenteric venous blood; NA -not available; OS -overall survival; PB -peripheral blood; PFS -progression-free survival; qPCR -quantitative real-time polymerase chain reaction; RFA -radiofrequency ablation; RT -radiotherapy; RT-PCR -reverse transcription polymerase chain reaction; TGFb1 -transforming growth factor b1; TRC method -transcription reverse-transcription concerted method

show abstract

Section: Colorectal Cancer (Crc)mentioning

confidence: 99%

Clinical studies monitoring circulating and disseminated tumor cells in gastrointestinal cancers

Eliasova

Kološtová

Kobierzycki

et al. 2014

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…This method allows identification of intact tumor cells occurring in the periphery for further characterization (Smirnov et al, 2005;Cohen et al, 2006). Most studies describing immunocytochemistry for the detection of DTCs in CRC patients either used the monoclonal antibody CK2 against CK18 or the pan-cytokeratin antibody A45-B/B3, while few studies employed a cocktail of several antibodies against different epithelial antigens including CKs.…”

Section: Detection Of Dtcs By Immunohistochemical Methodsmentioning

confidence: 99%

Cytokeratin 18 (CK18) and CK18 Fragments for Detection of Minimal Residual Disease in Colon Cancer Patients

Olszewski-Hamilton¹,

Buxhofer-Ausch²,

Hamilton³

2012

Cytokeratins - Tools in Oncology

View full text Add to dashboard Cite

“…The premise of the CellSearch method ( Figure 1) hence capitalizes on this EpCAM expression: epithelial cells from samples of peripheral whole blood are immunomagnetically enriched by incubation with EpCAM specific immunomagnetic ferrofluid, then stained with CD45, DAPI, and cytokeratins 8, 18, and 19. The bound cells are then magnetically separated out from unbound cells and fixed (21,22). To characterize a cell as a CTC, the following criteria are then applied: round to oval morphology, DAPI positive-staining to identify visible nuclei, positive staining for cytokeratin, and negative staining for CD45 to rule out leukocytes (21).…”

Section: Historymentioning

confidence: 99%

“…Using the CellSearch method, it was found that CTCs are rarely detected in the blood of normal patients, with ≥2 CTCs found in 0.3% of healthy and nonmalignant patients, whereas ≥2 CTCs were found in 36% of patients with metastatic carcinoma (21). The CellSearch method was subsequently shown to be feasible in isolating and characterizing CTCs from metastatic colorectal cancer (CRC) (22), and validated for clinical use in metastatic breast cancer (23). In 2011, Krebs et al showed the ability to detect CTCs in non-small cell lung cancer (NSCLC), with a change in CTC number correlating with therapeutic interventions and survival outcome (24).…”

Section: Historymentioning

confidence: 99%

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Nieva

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

An understanding of cancer evolution in lung cancer with its associated resistance to therapy can only be achieved with repeated sampling and analysis of the cancer. Given the high risks and costs associated with repeat physical biopsy, alternative technologies must be applied. Several modalities exist for analysis and re-analysis of cancer biology. Among them are the CellSearch platform, the CTC chip, and the highdefinition CTC platform. While the former is primarily able to provide prognosticating information in the form of CTC enumeration, the latter two have the advantage of serving as a platform to study tumor biology. Techniques for analysis of single cell genomics, as well as protein expression on a single cell basis provide scientists with the capacity to understand cancer cell populations as a collection of individual cells, rather than as an average of all cells. A multimodal combination of circulating tumor DNAs (ctDNAs), CTCs, proteomics, and CTC-derived xenografts (CDXs) to create computational models useful in diagnosis, prognostication, and predictiveness to treatment is likely the future of tailoring individualized cancer care.

show abstract

Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer

Cited by 166 publications

References 21 publications

Clinical studies monitoring circulating and disseminated tumor cells in gastrointestinal cancers

Clinical studies monitoring circulating and disseminated tumor cells in gastrointestinal cancers

Cytokeratin 18 (CK18) and CK18 Fragments for Detection of Minimal Residual Disease in Colon Cancer Patients

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Contact Info

Product

Resources

About